The simultaneous administration of low-dose MTX and Cilostazol could be an effective treatment strategy for mitigating joint deterioration and for attenuating of inflammation in RA by activating synovial fibroblasts' cAMP-dependent protein kinase and significantly reducing the production of cytokines, such as TNF-α, IL-1β, IL-6, and monocyte chemoattractant protein 1 (MCP1) in additive fashion (Kim et al. 2012). Here, CCL2 is linked to rheumatoid arthritis.